How Omnipod® 5 may deliver on psychosocial outcomes

Maintaining the consistent effort and attention required for successful glycaemic management can take a substantial toll on psychosocial wellbeing among people with diabetes and caregivers.1

Tubeless, waterproof* and discreet, the Omnipod® 5 Automated Insulin Delivery System with SmartAdjustTM technology consists of an on-body Pod communicating directly with a compatible sensor, and puts an end to daily injections.† Omnipod® 5 has demonstrated improved patient-reported outcomes as well as glycaemic control.2-4

* The Pod has an IP28 rating for up to 7.6 m (25 feet) for 60 minutes. The Omnipod® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 m (8 feet) of water for up to 24 hours without failure when properly installed.
† 1 Pod replaces up to 14 injections over 3 days (14 is the average number of injections over 3 days).

Successful management of T1D looks beyond glycaemic control1

When managing T1D, we must also consider the burden of diabetes on patients and caregivers. Multiple factors can contribute to diabetes distress among patients and their families, including fear of hypoglycaemia, concerns around eating and the relentless toll of day-to-day management.1,2 Consideration of these factors when implementing a new therapy is important.2,5

 

Omnipod® 5 users reported increased diabetes treatment satisfaction vs prior therapy in a pivotal study of adolescents and adults with T1D*2,3

 

Stress icon

Adults reported reduced diabetes distress compared to prior therapy

Mean diabetes distress scale (T1-DDS) score of 1.48 vs 1.64

badge icon

Adult users and caregivers felt confident in staying safe from the risk of hypoglycaemia compared to prior therapy

Mean hypoglycaemia confidence survey (HCS) score of 3.59 vs 3.34 and 3.65 vs 3.52, respectively

eating icon

Adults reported lower stress when eating compared to prior therapy

Eating distress survey (T1-DDS Eating Distress Subscale) score of 1.74 vs. 1.97

Sleeping icon

Caregivers reported a 38% improvement in sleep quality compared to prior therapy.

Mean PSQI Overall Sleep Quality Subscore of 0.70 vs 1.13, (comparison is relative change)

caregiver icon

Caregivers reported improved quality of life and mental well-being compared to prior therapy.2,3

* Compared to prior therapy: 14.3% multiple daily injection (MDI), 85.7% continuous subcutaneous insulin infusion (CSII). Assessed via the Diabetes Treatment Satisfaction Questionnaire (DTSQ).

See the Omnipod® 5 data

As well as delivering improvements in patient-reported outcomes, the Omnipod® 5 System has demonstrated improvements in glycaemic control.3,4

 

Improved glycaemic control

 

Contact our Medical Affairs or Medical Information teams

At Insulet, our aim is to keep on improving the lives of those living with T1D. With this in mind we aim to generate real-world data to provide further evidence on the efficacy of Pod Therapy. If you want to know more about our current trials and development pipeline do not hesitate to contact our Medical Affairs team at [email protected] or our Medical Information team at [email protected].

Arrange a meeting with an Omnipod® representative

Do you have questions about the Omnipod DASH® System? Our team is on call to provide you with the information you need and help you to determine which of your patients could best benefit from the Omnipod DASH® System.

Get in touch

Be the first to know

Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, Omnipod® published data and first-hand experiences from Podders®.

Subscribe

 

 

References: 1. Polonsky WH et al. Diabetes Care 2005;28:626-631. 2. Polonsky WH et al. Diabetes Res Clin Pract 2022;190:109998. 3. Brown SA et al. Diabetes Care 2021;44(7):1630-1640. 4. Sherr J et al. Diabetes Care 2022;45:1907-1910. 5. Battelino T et al. Diabetes Care 2019;42:1593–1603.